Novo Nordisk & Emisphere Announce Development Update

Novo Nordisk recently announced the Federal Food and Drug Administration (FDA) has approved Rybelsus, a semaglutide tablet, for the treatment of adults with type 2 diabetes. Oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, utilizes Emisphere Technologies, Inc.’s  proprietary Eligen SNAC Carrier Technology.

Rybelsus, the brand name for oral semaglutide in the US, is the first approved glucagon-like peptide-1 (GLP-1) receptor agonist in a tablet. The approval of Rybelsus is based on the results from 10 PIONEER clinical trials that included 9,543 adults with type 2 diabetes. Rybelsus more effectively lowered blood sugar than sitagliptin and empagliflozin. Furthermore, treatment with Rybelsus resulted in up to 4.4 kg reduction in body weight. Rybelsus demonstrated a safe and well-tolerated profile across the PIONEER program, with the most common adverse event being mild to moderate nausea which diminished over time.

“We are very excited that we can make the first oral GLP-1 available in the US and thereby expand the treatment options for adults living with type 2 diabetes,” said Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk. “Novo Nordisk has a very long legacy of developing innovative injectable medicines for people living with diabetes and, with the approval of Rybelsus, we are now able to bring our innovation into the market for oral antidiabetics.”

Novo Nordisk plans to make Rybelsus available to adults with type 2 diabetes in the US in the fourth quarter of 2019.

Emisphere is a drug delivery company that utilizes its proprietary Eligen Technology to develop new oral formulations of therapeutic agents. Emisphere is currently partners with global pharmaceutical companies for the development of new orally delivered therapeutics. For more information, visit